EUVIMEDEUVIMED entdecken
Crossref

Treatment of refractory pityriasis rubra pilaris with biologic therapy: a case series

Richard Han iD, William R Spratt, Howard Yang, Francis Y X Lai, Senhong Lee

Clinical and Experimental Dermatology · 2025

DOI: 10.1093/ced/llaf246 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Experimental Dermatology, 2025. Verfasst von Richard Han und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Monash Health, Melbourne, VIC, Australia. Hauptthemen laut MEDLINE: Pityriasis Rubra Pilaris, Dermatologic Agents, Biological Products. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 10 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pityriasis rubra pilaris (PRP) is a rare inflammatory dermatosis. There are limited data on its treatment with biologic therapies. We present a case series to evaluate the efficacy, time to primary response (TTPR) and tolerability of biologics in PRP management. A retrospective analysis of 11 patients with PRP treated with biologics at a tertiary Australian dermatology department was conducted. Patient demographics, prior therapies and treatment outcomes were reviewed. Biologics demonstrated variable efficacy: significant responses were seen with secukinumab (three of four, 75%), tildrakizumab (two of seven, 29%), ixekizumab (one of two, 50%) and risankizumab (one of one, 100%). Adalimumab yielded a partial response for two of three patients (67%). Combination therapy with systemic agents appeared to improve outcomes. Tildrakizumab had the shortest mean TTPR (6.8 weeks). Adverse effects were rare but led to treatment discontinuation in three patients. Sequential biologic therapy demonstrated some benefit to those who did not initially respond. These findings highlight the need for standardized treatment outcome measures and further research in PRP treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pityriasis Rubra PilarisDermatologic AgentsBiological ProductsHumansFemaleMaleRetrospective StudiesAdultMiddle AgedAntibodies, Monoclonal, HumanizedTreatment OutcomeAdalimumabAntibodies, MonoclonalAgedYoung Adult

Substanzen

Antibodies, Monoclonal, HumanizedDermatologic AgentsixekizumabAdalimumabsecukinumabtildrakizumabAntibodies, MonoclonalBiological Products

Autor:innen und Institutionen

  • Department of Dermatology, Monash Health, Melbourne, VIC, Australia.
  • Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, VIC, Australia.
  • Skin Health Institute, Melbourne, VIC, Australia.

ORCID-Profile: Richard Han

Zitieren

APA

Han, R., Spratt, W. R., Yang, H., Lai, F. Y. X., & Lee, S. (2025). Treatment of refractory pityriasis rubra pilaris with biologic therapy: a case series. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llaf246

Vancouver

Han R, Spratt WR, Yang H, Lai FYX, Lee S. Treatment of refractory pityriasis rubra pilaris with biologic therapy: a case series. Clinical and Experimental Dermatology. 2025. doi:10.1093/ced/llaf246

BibTeX
@article{Han2025,
  author = {Han, Richard and Spratt, William R and Yang, Howard and Lai, Francis Y X and Lee, Senhong},
  title = {Treatment of refractory pityriasis rubra pilaris with biologic therapy: a case series},
  journal = {Clinical and Experimental Dermatology},
  year = {2025},
  doi = {10.1093/ced/llaf246}
}
Kostenlos starten →